Rapid advances of immuno-oncology have triggered a new need for tumour models growing in immunocompetent mice. The syngeneic tumour models were mostly generated by inducing tumours in mice. Each model can develop subcutaneous or orthotopic tumours when implanted in the matching strain of immunocompetent mice.

Our approval for animal experimentation allows us to implant those models in C57BL/6, BALB/c, B6D2F1 and C3H. With a delay of a few weeks, we can obtain the agreement for other mouse strains.

In preclinical immuno-oncology, the syngeneic models are widely used to test combinations with approved Immune-Checkpoint Inhibitors like anti-PD1 or anti-PDL1. Amongst our syngeneic tumour models, we characterised several displaying primary resistances to anti-PD1 and/or anti-PDL1. These models of primary resistances complement our offer for secondary resistances.

Liquid tumours in Syngeneic models

Lymphoma
P388
On request
EL4
On request
2PK3
On request
Lymphocytic Leukemia
L1210
Download PDF
L5178Y
On request
Acute Myeloblastic Leukemia
NFS-60
On request
Myeloma
FO
Download PDF

Solid tumours in Syngeneic models

Bladder cancer
MB49
Download PDF
MBT-2
Download PDF
Breast Cancer
4T1
Download PDF
EO771
Download PDF
67NR
On request
NOP 23
On request
NEU 8,2
On request
NEU 15F1
On request
NEU 17+
On request
NEU 17R2
On request
Bone cancer
OSA
On request
K7M2
On request
MOS-J
On request
N2054
On request
Colon cancer
MC38
Download PDF
CT26
Download PDF
Fibrosarcoma
MCA-205
Download PDF
Kidney cancer
RENCA
Download PDF
Liver cancer
Hepa1.6
Download PDF
HepaRG
On request
Lung cancer
LL/2
Download PDF
Lymphoma
A20
Download PDF
Melanoma
B16-F10
Download PDF
Yumm1.7
Download PDF
TyrN-ras
Download PDF
N-ras
On request
Braf
Download PDF
Neuroblastoma
GT1-7
On request
Ovarian cancer
ID8
On request
Pancreatic cancer
Panc02
Download PDF
Panc02-H7
Download PDF
KIC8
On request

Contact our Team to learn more

Contact